AbbVie Gains European Commission Approval for Epcoritamab Combination in Relapsed Follicular Lymphoma

A new bispecific antibody combination now carries full European Commission marketing authorization, placing fresh demands on AbbVie's European biologics manufacturing, cold-chain infrastructure, and pharmacovigilance systems. The EC granted approval on 6 July 2026 for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, making it the first bispecific-based regimen authorized in Europe for this indication in the second-line setting.

The authorization rests on data from the pivotal Phase 3 EPCORE FL-1 trial, an open-label interventional study comparing fixed-duration epcoritamab plus R2 against R2 alone. The combination reduced the risk of disease progression or death by 79% (HR 0.21; 95% CI: 0.13–0.33; p<0.0001). Overall response rate reached 96% versus 81% for R2 alone, and 74% of patients in the combination arm achieved complete response compared with 43% in the control arm.

For QA directors and regulatory leads preparing the post-approval dossier, the safety profile carries direct implications for risk management planning. Serious adverse reactions occurred in 44% of patients receiving the combination. Cytokine release syndrome, pneumonia, COVID-19, and febrile neutropenia each appeared as serious adverse reactions in 5% or more of patients, signaling that pharmacovigilance teams will need robust CRS monitoring protocols embedded in the EU Risk Management Plan from launch.

On the manufacturing side, epcoritamab's bispecific antibody architecture introduces fill-finish complexity that differs materially from conventional monoclonal antibody processes. Supply chain leads managing European distribution will need to validate cold-chain continuity across the subcutaneous injection presentation, aligning with 21 CFR Part 211 equivalents under EU GMP Annex 1 and EMA expectations for biological medicinal products. The fixed-duration dosing schedule adds a defined commercial supply window that procurement and logistics teams can model against projected patient volumes across EU member states.

Follicular lymphoma accounts for 20–30% of all non-Hodgkin lymphoma cases, representing a substantial and recurring patient population; the second-line positioning of this approval means commercial uptake timelines are likely to be compressed relative to later-line launches.

The measurable benchmark for European operations will be how quickly AbbVie can demonstrate supply continuity and pharmacovigilance readiness to national competent authorities as member-state launches proceed.

Source: AbbVie News Center via PR Newswire, 6 July 2026.